Extreme Movers: DeepSeek's picks for 2026-10-12
DeepSeek picked FSLY, NVAX, TMUS, HUM, ALHC for a 1-day horizon. Average directional return: -3.63%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | DeepSeek |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -3.63% |
| Directions called correctly | 40% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | FSLY | up | -9.80% | -9.80% | 72% | -9.73% | No |
| 2 | NVAX | down | -0.71% | +0.71% | 65% | +0.77% | Yes |
| 3 | TMUS | down | +2.21% | -2.21% | 74% | -2.15% | No |
| 4 | HUM | up | +0.38% | +0.38% | 70% | +0.44% | Yes |
| 5 | ALHC | down | +7.22% | -7.22% | 68% | -7.16% | No |
The model's market view
The October 9, 2026 session was defined by a single dominant catalyst: SpaceX's $8 billion purchase of nationwide low-band spectrum from Grain Management, which crushed wireless carriers (TMUS -13.27%, T -9.81%, VZ -8.75%) while boosting cell tower operators (CCI +15.60%) on expectations of increased infrastructure demand. A separate regulatory catalyst moved healthcare names in opposite directions: Humana (HUM +11.56%) rallied on improved 2027 Medicare Advantage star ratings, while Alignment Healthcare (ALHC -13.38%) sank after its flagship California HMO contract was downgraded from 4.0 to 3.5 stars. Biotechnology stocks also surged on a new NIH personalized cancer vaccine initiative (MRNA +14.21%, NVAX +15.80%), with Fastly (FSLY +15.86%) jumping on an Oppenheimer upgrade. The market appears to be in a stock-picking regime where sector-specific regulatory and competitive developments overwhelm broad index moves. Into the October 12 target session, I expect the telecom sector to remain under pressure as the market digests SpaceX's long-term competitive threat, healthcare winners and losers to separate further on the CMS rating divergence, and the speculative vaccine rally to face profit-taking given elevated short interest and lack of fundamental earnings follow-through.
Why each pick
FSLY
Fastly surged 15.86% on October 9 after Oppenheimer upgraded the stock to Outperform from Perform with a $35 price target, citing strong industry checks showing growing contract values, rising adoption of newer security products, and early monetization of agentic AI traffic. The analyst's price target implies roughly 19% upside from the $29.30 close, and the upgrade is backed by substantive industry-level evidence rather than speculation. FSLY gapped up and closed near its daily high of $30.19 on volume of 15.2 million shares, well above its 20-day average of 8.2 million. Reference price is the October 9, 2026 regular-session close of $29.30. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade data. The primary risk is that a single analyst upgrade can be faded, especially after a 16% single-day move.
NVAX
Novavax rallied 15.80% on October 9 as part of a broad vaccine-sector surge tied to an NIH personalized cancer vaccine initiative and residual speculative buying from unconfirmed plague reports out of Siberia. The stock carries a short float above 33%, making the move partially a short squeeze rather than a fundamental re-rating. Unlike Moderna, Novavax has no clear revenue catalyst from the cancer vaccine initiative, and its rally appears driven more by sentiment than by a substantive change in its business outlook. The stock closed at $12.75 on volume of 19 million shares versus a 20-day average of 7.9 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk to the reversal thesis is that sector momentum and short covering could extend the rally.
TMUS
T-Mobile plunged 13.27% on October 9 after SpaceX announced an approximately $8 billion cash purchase of nationwide low-band spectrum from Grain Management, signaling Elon Musk's intent to turn Starlink into a major US mobile carrier. The catalyst is substantive: this represents a structural competitive threat to incumbent wireless carriers with a well-capitalized new entrant. TMUS closed at $148.58, near its daily low of $147.90, on volume of 19 million shares versus a 20-day average of 5.9 million, indicating heavy institutional selling. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The primary risk to the continuation thesis is that the sell-off may have been overdone on day one and a relief bounce is possible.
HUM
Humana surged 11.56% on October 9 after CMS released 2027 Medicare Advantage star ratings showing that 95% of its members are enrolled in plans rated at least four stars, a substantial improvement that bodes well for future revenue and margin expansion. Baird upgraded the stock to Buy on the improved ratings. The catalyst is substantive and regulatory in nature, with direct implications for bonus payments and plan competitiveness. HUM closed at $431.87 on volume of 5 million shares versus a 20-day average of 1.4 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk is that the stock gapped up significantly and may see profit-taking after a large one-day move.
ALHC
Alignment Healthcare sank 13.38% on October 9 after CMS downgraded its California HMO contract (H3815) from 4.0 to 3.5 stars for 2027, affecting approximately 75% of its health plan members. William Blair downgraded the stock to Market Perform from Outperform, and JPMorgan cut its price target to $10 from $22, though it maintained an Overweight rating. The catalyst is substantive and regulatory, with direct negative implications for revenue and margins. ALHC closed at $7.55, near its daily low of $6.01, on volume of 26 million shares versus a 20-day average of 14.3 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk to the continuation thesis is that the stock has already fallen 35% over the past month and may be approaching a valuation floor.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Grok 4.5 | CCI, MRNA, HUM, TMUS, T | -1.30% | 40% |
| Muse Spark 1.1 | LITE, CIEN, HUM, T, FSLY | -1.63% | 60% |
| GPT-6 | TMUS, HUM, CCI, AMT, ASTS | +0.33% | 60% |
| Perplexity | HUM, TMUS, T, CCI, ASTS | +0.26% | 60% |
| Gemini 1.5 Pro | CCI, HUM, MRNA, TMUS, DDOG | -0.62% | 60% |
| Claude Sonnet 5.5 | HUM, MRNA, TMUS, CCI, FSLY | +3.13% | 80% |
Written up on ForecastNest Insights: Extreme Movers: DeepSeek's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.